Osteoporosis, a high-incidence chronic disease, is known to cause physical pain, even leading to disability of patients, and creates a vast social burden. To improve the shortcomings of the current clinical osteoporosis treatment drugs, several studies have designed a multitude of nanomedicines to optimize traditional drugs based on the TOP-DOWN design. Fascinating nanomedicine designs are breathing vitality into traditional osteoporosis drugs. However, considering the unique pathological characteristics of osteoporosis and clinical treatment needs, we should also pay attention to the problems outside the spotlight. Here, we reviewed the current clinical osteoporosis treatment drugs, summarized their limitations, and generalized the nanomedicines designed based on the TOP-DOWN strategy for the mentioned deficiencies. In addition, we explored the issues outside the spotlight of the nanomedicine design for the treatment of osteoporosis because of the gap between laboratory design strategy and clinical demands and then determined the rational design of nanomedicines for osteoporosis.
Keywords: Osteoporosis; nanomedicine; traditional drug.